Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Thursday, June 30, 2022.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2022 (2022-06-30): -212.09%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-136.70%
RETURN ON EQUITY (ROE) AVG 3Y
-59.90%
RETURN ON EQUITY (ROE) AVG 5Y
-34.32%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Kyntra Bio, Inc.
Market Cap
$24.09M
Return on Equity (ROE)
N/A
TTM Avg
-136.70%
3Y Avg
-59.90%
5Y Avg
-34.32%
Market Cap
$24.68M
Return on Equity (ROE)
-76.82%
TTM Avg
-235.52%
3Y Avg
-335.24%
5Y Avg
-272.42%
Market Cap
$24.74M
Return on Equity (ROE)
-140.55%
TTM Avg
-62.02%
3Y Avg
-44.98%
5Y Avg
-43.41%
Market Cap
$23.04M
Return on Equity (ROE)
-487.90%
TTM Avg
-205.19%
3Y Avg
-102.69%
5Y Avg
-68.50%
Market Cap
$25.47M
Return on Equity (ROE)
-83.26%
TTM Avg
-46.97%
3Y Avg
-39.40%
5Y Avg
-27.49%
Market Cap
$22.36M
Return on Equity (ROE)
-421.06%
TTM Avg
-298.11%
3Y Avg
-181.82%
5Y Avg
-125.27%
Market Cap
$22.11M
Return on Equity (ROE)
-40.40%
TTM Avg
-55.95%
3Y Avg
-53.10%
5Y Avg
-83.38%
Market Cap
$21.76M
Return on Equity (ROE)
-260.37%
TTM Avg
-164.08%
3Y Avg
-188.26%
5Y Avg
-64.22%
Market Cap
$20.80M
Return on Equity (ROE)
-313.46%
TTM Avg
-251.20%
3Y Avg
-178.74%
5Y Avg
-144.62%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kyntra Bio, Inc. (KYNB) | $24.09M | N/A | -136.70% | -59.90% | -34.32% |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.68M | -76.82% | -235.52% | -335.24% | -272.42% |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.74M | -140.55% | -62.02% | -44.98% | -43.41% |
| Rein Therapeutics Inc. (RNTX)vs › | $23.04M | -487.90% | -205.19% | -102.69% | -68.50% |
| iTonic Holdings Ltd. (ITOC)vs › | $25.47M | -83.26% | -46.97% | -39.40% | -27.49% |
| LeonaBio, Inc. (LONA)vs › | $22.36M | -421.06% | -298.11% | -181.82% | -125.27% |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.11M | -40.40% | -55.95% | -53.10% | -83.38% |
| Modular Medical, Inc. (MODD)vs › | $21.76M | -260.37% | -164.08% | -188.26% | -64.22% |
| Quantum BioPharma Ltd. (QNTM)vs › | $20.80M | -313.46% | -251.20% | -178.74% | -144.62% |
| Seres Therapeutics, Inc. (MCRB)vs › | $27.74M | -65.05% | -525.23% | -779.21% | -536.29% |
ROE
N/A
ROA
181.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2022-06-30 | -212.09% |
| 2022-03-31 | -178.09% |
| 2021-12-31 | -138.67% |
| 2021-09-30 | -65.86% |
| 2021-06-30 | -88.79% |
| 2021-03-31 | -49.24% |
| 2020-12-31 | -44.84% |
| 2020-09-30 | -50.65% |
| 2020-06-30 | -78.62% |
| 2020-03-31 | -23.98% |
| 2019-12-31 | -14.91% |
| 2019-09-30 | 7.08% |
| 2019-06-30 | 7.79% |
| 2019-03-31 | -18.49% |
| 2018-12-31 | -16.97% |
| 2018-09-30 | -27.48% |
| 2018-06-30 | -25.16% |
| 2018-03-31 | -26.91% |
| 2017-12-31 | -22.41% |
| 2017-09-30 | -24.16% |
| 2017-06-30 | -54.11% |
| 2017-03-31 | -50.87% |
| 2016-12-31 | -39.58% |
| 2016-09-30 | -44.32% |
| 2016-06-30 | -51.78% |
| 2016-03-31 | -42.85% |
| 2015-12-31 | -48.31% |
| 2015-09-30 | -39.11% |
| 2015-06-30 | -31.31% |
| 2015-03-31 | -48.55% |
| 2014-12-31 | -26.88% |
| 2014-09-30 | -43.68% |
| 2014-06-30 | 38.50% |
| 2014-03-31 | -20.39% |
| 2013-12-31 | -18.74% |
